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Abstract
Background
Intellectual disability (ID) is relatively common in people with epilepsy, with prevalence esti-
mated to be around 25%. Surprisingly, given this relatively high frequency, along with higher
rates of refractory epilepsy than in those without ID, little is known about outcomes of differ-
ent management approaches/clinical services treating epilepsy in adults with ID—we inves-
tigate this area.
Materials & methods
We undertook a naturalistic observational cohort study measuring outcomes in n = 91 adults
with ID over a 7-month period (recruited within the period March 2008 to April 2010). Partici-
pants were receiving treatment for refractory epilepsy (primarily) in one of two clinical ser-
vice settings: community ID teams (CIDTs) or hospital Neurology services.
Results
The pattern of comorbidities appeared important in predicting clinical service, with Neurolo-
gists managing the epilepsy of relatively more of those with neurological comorbidities whilst
CIDTs managed the epilepsy of relatively more of those with psychiatric comorbidities. Epi-
lepsy-related outcomes, as measured by the Glasgow Epilepsy Outcome Scale 35 (GEOS-
35) and the Epilepsy and Learning Disabilities Quality of Life Scale (ELDQoL) did not differ
significantly between Neurology services and CIDTs.
Discussion
In the context of this study, the absence of evidence for differences in epilepsy-related out-
comes amongst adults with ID and refractory epilepsy between mainstream neurology and
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specialist ID clinical services is considered. Determining the selection of the service manag-
ing the epilepsy of adults with an ID on the basis of the skill sets also required to treat associ-
ated comorbidities may hence be a reasonable heuristic.
Introduction
Epilepsy is common in adults with intellectual disability (ID), as the most frequent serious
medical illness experienced by this clinical group [1], with an overall prevalence of around
26% [2]. Epilepsy in adults with ID has a worse prognosis than epilepsy in the general popula-
tion, with lower rates of seizure freedom [3] and high rates of multiple anti-epileptic drug use
[4], which incur more side-effects [5]. Adults with ID and epilepsy also have high rates of mor-
bidity [6] and mortality, including sudden unexplained death in epilepsy [7]. Poorly controlled
and inadequately treated epilepsy also impacts negatively on the quality of life of adults with
ID and epilepsy, and associated consequences affect families and paid carers [8–9].
Surprisingly, given these poor outcomes, little is known about the best approach to epilepsy
management for this population and guidelines are largely based on anecdote or clinical con-
sensus [10]. Among those with epilepsy, people with ID have a greater prevalence of complex
comorbidities to deal with relative to those without ID [11–12]. These comorbidities can often
interact with their epilepsy, making their care and treatment even more challenging. This has
resulted in some regions having a wide range of healthcare providers delivering aspects of epi-
lepsy-related care to adults with ID (ranging from primary care, to specialist community health
services for people with ID, to Neurology services). Neurology services tend to be based in sec-
ondary or tertiary care health care settings, with a focus on treating neurological disease;
whilst, in the UK, multidisciplinary health teams for people with ID (CIDTs) are based in the
community and generally have a wider remit, managing a range of psychobehavioural morbid-
ities and functional difficulties. Given this choice of potential healthcare providers it is impor-
tant to consider whether there are differences between providers in terms of the patients they
treat and the outcomes they obtain. Previous research in one region of England has demon-
strated that most adults with ID and epilepsy receive their epilepsy management from commu-
nity-based ID services or from hospital-based Neurology services, whilst a smaller proportion
receive epilepsy management from multiple sources including General Practitioners [4]. This
current disposition of epilepsy services for adults with ID and epilepsy in the UK provides a
natural situation in which to investigate the type of person using the different types of service
and whether individuals fare better in one type of service than in another.
Therefore, using an observational cohort methodology, we have undertaken research to test
the hypothesis that amongst 91 adults with ID and epilepsy, recruited from community ID
teams (CIDTs) or hospital Neurology services, there are differences between the recipients of
these two services. The results from this study may help those who commission and design ser-
vices as well as clinicians to determine which service is best suited to supporting a particular
individual’s epilepsy.
Materials & methods
Participant recruitment, inclusion criteria and sample size
Recruitment and data collection took place between March 2008 and April 2010. Eligible par-
ticipants comprised all adults aged between 18 and 65 years with epilepsy and at least one
Epilepsy management in adults with intellectual disabilities
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seizure in the preceding 6 months, with a diagnosis of a full scale IQ below 71, living in Cam-
bridgeshire or Norfolk and known to community ID and/or hospital Neurology services.
Potential participants were initially identified by the clinicians managing their epilepsy. All
potential participants identified (334) were contacted and 198 replied. Of these, 28 were ineli-
gible and in 79 cases consent or agreement from a consultee was not given, leaving 91 individ-
uals to participate in the study (who provided informed written consent, or for whom a
written favourable opinion from a consultee was given, as appropriate). For those lacking
capacity to consent, advice was sought from a carer under the provisions of the Mental Capac-
ity Act [13]. Forty six (51%) of the 91 participants were male. The mean age of participants was
41.3 years (standard deviation, SD = 11.8) and the mean duration of epilepsy was 30.7 years
(SD = 16.1, in the 79 participants providing this data). The study was approved by the Cam-
bridgeshire 2 Research Ethics Committee.
Study design and data collection
Following recruitment, each participant was visited five times over a period of seven months
in order to obtain repeated measures of their clinical state, which could be averaged over a
period of time. This aims to reduce the effect on these observations of the short-term variabil-
ity in seizure frequency that occurs in a proportion of those with epilepsy.
During the first visits to participants’ homes, consent or favourable advice was obtained
and background information was collected describing the participant’s epilepsy and its treat-
ment, ID severity and comorbid medical conditions, along with details of their accommoda-
tion. The subsequent visits occurred at around one, two, six and seven months after the initial
visit. During these four subsequent assessment visits, qualitative information, health economic
data and outcome measures, including the Glasgow Epilepsy Outcome Scale 35 (GEOS-35)
and the Epilepsy and Learning Disabilities Quality of Life Scale (ELDQoL), were collected. In
this paper we restrict our attention to clinical outcomes described by the GEOS-35 and the
ELDQoL. Analysis from other measures has been reported elsewhere [14–15].
Measures
GEOS-35. The GEOS is a carer-reported measure of outcomes in epilepsy developed for
use with people who have ID. The GEOS-35 is a short form of the GEOS-90 [16], comprising
four sub-scales recording the informant’s concerns about: Seizures (10 items); Medical treat-
ment (9); Caring for a person with epilepsy (8); and Social impact of epilepsy (8). GEOS items
require responses that are rated on a five point scale, from “0 –never a concern/not applicable”
to “4 –very often a concern”. A higher score on any of the sub-scales, or the overall score, indi-
cates a greater level of concern. Espie et al. [17] show that both the GEOS-90 and GEOS-35
have good internal consistency (Cronbach’s alpha>0.8), and acceptable discriminant and con-
current validity.
We aimed to complete the GEOS-35 on the first and fourth assessment visits. The measure
was either completed by a family carer or paid support worker. Differences in concerns
reported by different types of carer have been investigated: high inter-rater agreement was
found between family members but there was considerable variability between support work-
ers [18]. Thus, when support workers completed this form, we sought to have the same indi-
vidual complete the measure at both collection points. In the following analyses, for each sub-
scale and for the overall score, we use the mean of scores from assessment one and assessment
four. For seven participants the GEOS-35 was completed only once.
ELDQoL. The ELDQoL is a 70 item carer-reported measure examining seizure severity,
seizure related injury, Anti-Epileptic Drugs (AED) side effects, behaviour, mood, physical
Epilepsy management in adults with intellectual disabilities
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status, cognitive and social functioning, communication, overall health and quality of life, and
family concerns. Particular items in the Seizure severity (14 items), Side effects (19), Behaviour
(9) and Mood (16) domains can be summed to create four sub-scales. Higher scores indicate a
poorer quality of life. Buck et al. [19] explore the ELDQoL psychometric properties for collect-
ing information about epilepsy in children and find that the ELDQoL has: good internal con-
sistency (Cronbach’s alpha: 0.74–0.95); high reliability (range: 0.8–0.96); and good construct
validity. While not validated for use with adult participants, other studies have used it with this
group [20–22].
The ELDQoL was completed at each of the four assessment visits, gathering information
about the participant’s epilepsy over the preceding four weeks. The Seizure severity sub-scale
was completed separately for each type of seizure experienced by a participant, up to a maxi-
mum of five seizure types. Overall seizure severity was quantified for each participant as the
mean of mean scores for each seizure type, providing an indication of the average severity of
their epilepsy over that period.
Dealing with missing data
Where a participant’s score on a sub-scale of a measure was affected by items with missing
data, the missing values were replaced with an average of the items with complete data. This
imputation only took place if more than 50% of items on any sub-scale had complete data;
where more than 50% of the items on a scale were missing data, the participant was recorded
as having a missing value for that particular sub-scale. Otherwise, no methods were used to
correct for missing data; however, levels of missing data were generally low (particularly on
the outcome measures).
Analysis
We deal with the following types of data in this paper: first, ‘casemix’ variables (variables that
describe the following aspects of each participant: ID severity; accommodation type; total
number of AEDs taken by each participant; whether or not an Epilepsy Nurse Specialist has
been seen in the preceding year; the presence of current comorbid neurological diagnoses; the
presence of current comorbid psychiatric diagnoses; and the number of seizure types); sec-
ondly, we consider their clinical service (comprising CIDT, Neurology and ‘Other’); and
thirdly, their scores on the outcome scales (GEOS-35 and ELDQoL). We proceed by identify-
ing the primary clinical service supporting individuals by using latent class analysis (LCA).
Subsequently, we use logistic regression to compare the casemix profiles between the CIDT
and Neurology services. Wilcoxon tests were used to compare GEOS-35 and ELDQoL out-
comes between CIDT and Neurology services.
Results
Identification of the treating clinical service
There was a lack of clarity in the identification of which service was responsible for epilepsy
management for some participants, as in some instances there were differing opinions between
the participant’s main carer, GP, ID Psychiatrist (if involved) and Neurologist (if involved).
There were sixteen cases where there was disagreement between two or more of the opinions:
seven cases went on to be identified as having their epilepsy managed by CIDT, four by Neu-
rology and five fell into the ‘Other’ category. In fifteen of the sixteen cases, there was disagree-
ment between carer and GP opinions. The corresponding patients had the full range of LD
severity (mild—two; moderate—four; severe—six; profound—three), and mostly lived in
Epilepsy management in adults with intellectual disabilities
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group homes or supported living (nine) or the family home (six), with one patient living
independently.
Therefore, to allocate participants to a clinical service, we used a model-based approach
based on LCA. Latent class modelling has similar goals to cluster analysis (grouping individu-
als) but is based on a statistical model, not distance metrics. Our modelling used LCA to com-
pare the fit of models with 2, 3 or 4 latent classes. The data supplied to the model were the
opinions as to the managing clinician from the participant’s main carer, GP, LD Psychiatrist
(if indicated) and Neurologist (if indicated) [23]. The model tries to find homogeneous groups
within which, once we know their group membership (latent classification) there is no further
association among the observed data (their responses). In this way, as we increased the number
of classes, the LCA found a model that allocated participants to one of three groups used in
our analyses [24]. Utilising LCA in this way allowed us to resolve disagreements in a pragmatic
fashion that required no initial assumptions from the research team about whose opinions
should take priority; otherwise, we might have to make subjective assumptions (eg in case of
disagreement, assume the opinion of the GP is correct) or exclude those cases where there is
disagreement.
Utilising LCA, forty-two participants were identified as having their epilepsy care managed
by a CIDT and 37 as having it managed by a Neurology service. The ‘Other’ group consisted of
11 participants where epilepsy management was either provided only by the GP or by a combi-
nation of services, with no clear indication of which service led treatment. One participant was
not assigned to any of these groups. The identity of the managing clinical service, as reported
by the informants, did not change for any of the participants during the study.
Profile of casemix variables within each clinical service
Table 1 shows the profiles of casemix variables within each of the clinical services. Contrasting
the Other group with CIDT and Neurology is difficult since it contains few study participants;
however, Table 1 suggests that the Other group is more likely to contain people with severe or
profound ID, with a current comorbid neurological diagnosis, who are taking fewer anti-epi-
leptic drugs. We do not consider the Other group further.
Differences in casemix variables between CIDT and Neurology services were tested in R
[25] using both unadjusted univariate comparisons (Fisher’s exact test and two sample t-tests)
and adjusted comparisons utilising logistic regression. The results of the tests are given in
Table 2.
Confidence intervals for the odds ratios are wide given the small sample. Whilst the profile
of ID severity between the clinical services did not differ significantly, it was included a priori
as a proxy for features not captured by the casemix variables employed. We found that, com-
pared to ID services, Neurology services were more likely to: support those living in a family
home or independently, as opposed to residing in a group home or supported living environ-
ments; treat using more anti-epileptic drugs; support those with a current comorbid neurolog-
ical diagnosis; and support those who had seen an Epilepsy Nurse Specialist in the preceding
twelve months. Neurology services less frequently managed the epilepsy of those with a current
comorbid psychiatric diagnosis. The direction of observed differences is the same in the unad-
justed and adjusted comparisons, but the effects are much stronger in the adjusted
comparisons.
Differences in GEOS-35 and ELDQoL outcomes by clinical service
Table 3 shows who completed the GEOS-35 (completed up to two times) and the ELDQoL
(completed up to four times). Within each measure, the majority of returns for each patient
Epilepsy management in adults with intellectual disabilities
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were completed by the same informant (top two rows of Table 3). A larger proportion of infor-
mants for CIDT were (paid) carers, while there was closer to an equal split between carers and
family in Neurology. GEOS-35 and ELDQoL returns differ between themselves and the num-
bers given in Table 1 due to some informants not completing some measures.
Table 4 shows the average outcome scales scores for each clinical service. Based on indepen-
dent Wilcoxon tests, at the 5% level of significance, no significant differences in GEOS-35 or
ELDQoL outcomes were found between those receiving their epilepsy management from a
CIDT and those receiving it from a Neurology service.
Discussion
Treating epilepsy in adults with ID may be complicated by the presence of a wide range of
impairments, the relatively frequent presence of comorbid conditions and by the various resi-
dential arrangements used by people with ID. Addressing the challenges associated with these
complexities has led to the development of a variety of potential treatment services differing in
their skill sets and treatment focus. Thus, the question arises as to whether particular clinical
services should be directed towards particular sub-groups of patients.
In the UK most epilepsy management for adults with ID is provided by Neurology or
CIDTs or some combination of these services, with varying involvement from primary care
professionals. Little research has been undertaken to investigate differences between these set-
tings and services. The aims of this study were to investigate possible differences amongst indi-
viduals with ID and epilepsy, between those receiving support from one of these two service
alternatives, either in terms of their individual characteristics (described here as casemix vari-
ables) or in terms of their outcomes (ELDQoL and GEOS-35) on established instruments.
In considering these issues, we noted that it was not always clear which clinical service was
responsible for directing the management of an individual’s epilepsy. We therefore recom-
mend that where more than one clinical service becomes involved in delivering epilepsy-
related healthcare to an individual with ID, the relative roles of each are clearly defined and
Table 1. The profile of patient heterogeneity (‘casemix’) variables within each of the clinical services and the Other group. CIDT = Community Intel-
lectual Disability Team. ENS = Epilepsy Nurse Specialist.
Case mix variable CIDT (N = 42) Neurology (N = 37) Other (N = 11)
Severity of intellectual disability Mild 15%* 20%† 0%
Moderate 20%* 31%† 18%
Severe 49%* 31%† 45%
Profound 17%* 17%† 36%
Accommodation Group home/supported living 74% 49% 73%
Family home 21% 41% 27%
Independent 5% 11% 0%
Anti-epileptic drugs used 2 71% 81% 45%
ENS seen in last year Yes 7% 46% 0%
Current comorbid neurological diagnosis Present 10% 16% 36%
Current comorbid psychiatric diagnosis Present 52% 32% 18%
Seizure types reported 1 48% 46%† 64%
2 45% 34%† 27%
3 7% 20%† 9%
*N = 41.
†N = 35. Percentages may not sum to 100 due to rounding.
https://doi.org/10.1371/journal.pone.0180266.t001
Epilepsy management in adults with intellectual disabilities
PLOS ONE | https://doi.org/10.1371/journal.pone.0180266 July 3, 2017 6 / 12
agreed by all concerned. In the small number of study participants for whom the service pri-
marily responsible for managing their epilepsy could not be established there was a relative
preponderance of people with severe (5/11) or profound (4/11) ID, a diagnosis of a current
neurological comorbidity, and prescription of fewer anti-epileptic drugs. This may indicate
Table 2. Unadjusted and adjusted comparisons in casemix variables (along with gender and age) between CIDT (reference level) and Neurology.
Unadjusted univariate comparisons made using Fisher’s exact test or two sample t-test (for age). Adjusted comparisons are estimated from a
logistic model (with service type as response variable) including all the variables listed in the Table. OR = odds ratio. ENS = epilepsy nurse specialist.
diag = diagnosis.
Model term Level N Unadjusted Adjusted
OR/mean 95% CI Odds ratio 95% CI
Lower Upper Lower Upper
Severity of intellectual disability Mild 12 - - - -
Moderate 18 1.24 0.23 6.85 8.90 0.65 210.95
Severe 31 0.56 0.12 2.65 1.27 0.10 18.89
Profound 13 0.86 0.14 5.36 0.48 0.02 10.85
Accommodation Group home or supported living 45 - - - - -
Family home 24 3.27* 1.06 10.71 50.89* 5.70 850.28
Independent 5 2.93 0.30 38.63 46.68 0.99 4537.41
Total number of anti-epileptics 0 or 1 18 - - - - -
2 or more 56 1.85 0.55 6.89 11.23* 1.54 137.83
Seen an ENS during last year? No 57 - - - -
Yes 17 9.04* 2.16 54.97 55.58* 8.03 758.67
Current comorbid neurological diag. No 64 - - - -
Yes 10 2.04 0.43 10.81 12.90* 1.60 146.91
Current comorbid psychiatric diag. No 42 - - - -
Yes 32 0.48 0.16 1.35 0.06* 0.01 0.32
(Max) Seizure types reported One 33 - - - - -
Two 31 0.86 0.28 2.61 0.76 0.14 4.13
 three 10 3.08 0.57 21.79 4.52 0.49 50.20
Gender Male 35 - - - - - -
Female 39 0.92 0.33 2.54 0.77 0.17 3.43
Age (years) CIDT mean - 41.83 38.22 45.44 1.05 0.98 1.14
Neurology mean - 39.91 39.91 44.51
Intercept - - - - - 0.00* 0.00 0.36
‘*’ denotes significance at the 5% level. CI = Confidence Interval. R2 = .45 (Hosmer-Lemeshow), .46 (Cox-Snell), .61 (Nagelkerke). χ2(11) = 45.296,
p<0.001
https://doi.org/10.1371/journal.pone.0180266.t002
Table 3. Details of who completed the GEOS-35 and ELDQoL measures, from which the scales used to compare the clinical services in Table 4 are
formed.
Respondent type GEOS-35 returns (completed up to 2
times)
ELDQoL returns (completed up to 4
times)
CIDT Neurology CIDT Neurology
All returns completed by the same carer 27 14 25 14
All returns completed by the same family member 10 14 9 14
Returns completed by different carers 5 5 7 5
Returns completed by different family members 0 0 1 2
Returns completed by a mix of carers and family members 0 2 0 2
https://doi.org/10.1371/journal.pone.0180266.t003
Epilepsy management in adults with intellectual disabilities
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that those with the most severe and complex physical comorbidities find it more difficult to
access any secondary care services, suggesting that clinicians should pay special attention to
how the most severely disabled are treated
Turning to the comparison of characteristics of the participants being supported by CIDT
to those being supported by Neurology, some differences were seen in patterns of psychiatric
comorbidity and accommodation, but no significant overall differences were found in the pro-
file of ID severity or the number of seizure types reported (Table 2). This suggests that the
placement within a particular type of clinical service, at this stage in the participants’ epilepsy
career, may not directly relate to their level of ID or their epilepsy. Further, given that differ-
ences in ID level were controlled for in the above comparison, the observations that partici-
pants whose epilepsy care was managed by a Neurology service were more likely to live in the
family home and less likely to have a current comorbid psychiatric diagnosis cannot be
explained by these participants having less severe ID. It was also noted that participants under
the care of Neurology services were more likely to have seen an Epilepsy Nurse Specialist
within the last year: this difference arose as a consequence of the majority of CIDTs included
in the study area not having an Epilepsy Nurse.
Considering the comparison of outcome measures describing seizure severity and epilepsy-
related quality of life, we examined participants’ scores on the GEOS-35 and ELDQoL. No sig-
nificant differences were found between participants managed by CIDT and Neurology in
terms of these outcome measures. These results can be interpreted to suggest that either the
choice of clinical service does not affect a service user’s outcome (as measured by these scales),
or, if the choice of service did originally affect a service user’s outcomes, the differences dimin-
ish over time and are no longer evident years later. This may reflect that service users are being
supported by the most appropriate clinical service and in both services are being helped as far
as current treatments permit. Alternatively, it may reflect that it does not matter which service
supports a service user; perhaps, on average, both services eventually achieve a similar level of
outcome. However, this comparison of outcomes between the clinical services takes no
account of individual patient characteristics (as measured by the casemix variables), which
were found to be reasonable predictors of scores (explaining notable proportions of variation:
0.2<R2<0.5 –see S1 Table) on the outcome measures. Thus, when comparing outcomes
between clinical services, the outcomes would ideally have been adjusted to take account of the
individual participant characteristics. However, we have not done this as our sample size
would not robustly support such comparisons.
Table 4. The profile of outcome scales variables within each of the clinical services and the Other group. GEOS-35 = Glasgow Epilepsy Outcome
Scales-35. ELDQoL = Epilepsy and Learning Disabilities Quality of Life. CIDT = Community Intellectual Disability Team.
Scale Scale
details
Medians Wilcoxon test of CIDT and Neurology
scores
Min Max CIDT (N = 41) Neurology (N = 32) Other (N = 10)
GEOS-
35
Seizures 0 40 9.5 8.0 6.1 W = 759, p = 0.8100
Medical treatment 0 36 6.2 6.8 6.9 W = 716, p = 0.8499
Caring 0 32 4.4 6.5 2.7 W = 595, p = 0.2155
Social impact 0 32 2.9 5.9 2.4 W = 550, p = 0.1155
GEOS-35 Total 0 140 23.8 30.3 17.5 W = 705, p = 0.7641
ELDQoL Seizure severity (mean-
avg)
10 56 25.6 24.6 23.7 W = 765, p = 0.7628
Side effects 19 76 25.2 24.7 23.6 W = 712, p = 0.7907
Behaviour 9 36 15.0 14.7 18.2 W = 848, p = 0.4915
Mood 16 64 30.7 28.7 31.4 W = 896, p = 0.1620
https://doi.org/10.1371/journal.pone.0180266.t004
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This study has a number of limitations. The work presented here is one part of a larger
descriptive body of work investigating epilepsy treatment in those with ID using the recruited
cohort: we explore the cost drivers of epilepsy treatment in this population in Pennington et al.
[14] whilst Redley et al. [15] looks at the involvement of parents in decision making around
epilepsy treatments. As such, there was no single outcome or variable that we were primarily
focused and so, with no primary outcome, a sample size calculation was not appropriate. This
means that the study was not powered to detect differences between the management path-
ways on the GEOS-35 and ELDQoL (or other differences). Thus, the lack of statistical differ-
ences in these outcomes may be caused by a lack of statistical power. Further, as noted above,
we were not able to adjust the outcome comparison for patient characteristics, due to the sam-
ple size (small in absolute terms, but from a difficult to recruit vulnerable population).
The study is also limited by having a cross-sectional design, which limits some of the ques-
tions we can address. We cannot explore how outcomes fluctuate within the pathways over
time. Also, we do not have access to data describing participants’ state at the time of initial
referral to the clinical service in which their epilepsy was first managed. Therefore, we cannot
comment on the reasons for their referral to one service rather than the other, or comment on
earlier aspects of their care pathway experience. To explore outcomes over time and collect
robust historical data on the patient treatment would require a participant-demanding longi-
tudinal study in this vulnerable population. However, the cross-sectional study reported here
can help focus future research questions, in that we describe individuals, their epilepsy man-
agement and related variables in the midst of what for many of the study population has been
a very long-term condition, addressing the question of what factors to consider when identify-
ing an appropriate care pathway for individuals with chronic complex comorbidities.
We have not been able to explore the extent of any selection bias. This is potentially con-
cerning, particularly as only 30% (91/306) of eligible patients consented. However, low consent
rates are not unusual for research in ID: in Perez et al. [26]–a study looking at adverse out-
comes in adults with ID and mealtime support—only 142 consent to take part out of an identi-
fied population of 726, a rate of 20%. It is difficult to recruit from the ID population for many
reasons, such as the capacity to consent and, relatedly, the frequent need to include family and
carers in the research. Unfortunately, we did not have ethical permission to retain the data of
non-responders or of the non-consenting population and so cannot conduct a non-responder
analysis to compare the characteristics of those that did and did not consent. However, we can
compare some of our consenter characteristics with a meta-analysis conducted by Robertson
et al. [27] that considers 48 studies of epilepsy in people with ID. We found that 15% of our
sample had mild ID, while the remaining 85% had more severe ID; this compares with a split
of 17.5% and 82.5% within the meta-analysis of Robertson et al [27]. Further, the meta-analysis
shows the prevalence of epilepsy within people with ID to be similar in both males (24.8%,
95% CI: 19.6–30.8%) and females (22.2%, 95% CI: 17.3–28.1); therefore in our sample, all of
whom have ID and epilepsy, we would expect a near equal split between the sexes—this is
observed (51% male/49% female). Hence, for at least these parameters, there is evidence for
our population being representative of the wider population with ID and epilepsy.
In summary, this research has demonstrated that, when looked at cross-sectionally, there is
no difference in seizure severity and epilepsy-related quality of life between those adults with
ID and epilepsy whose seizures are managed by a Neurology service and those whose seizures
are managed by a CIDT. With respect to the question of why participants were receiving care
from one type of service rather than another, the original reason for referral was not investi-
gated in this study. However, it is noted that there were differing rates of comorbidity, with
those in Neurology services having more neurological comorbidities whilst those in CIDTs
had more psychiatric comorbidity. The question as to whether this pattern reflects reasons
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behind the original choice of referral route or perhaps suggests that Neurologists identify addi-
tional neurological diagnoses whilst patients in CIDTs, staffed by mental health and social care
staff, are more likely to be diagnosed with psychopathology, remains to be established.
Supporting information
S1 Table. The structure of final linear models relating casemix variables to the outcome
scales.
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